Indications › Obesity & overweight › exenatide

exenatide in obesity & overweight

exenatide is not approved in the US for obesity & overweight, and has 29 trials on file here in this condition. 21 of them are phase 3 or later. No trial here has a completion date still in the future, so this is a closed body of work rather than an active programme. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

29 registered trials study exenatide (Bydureon, Byetta) in obesity & overweight, 1 of them still active and 1 in phase 3. None has a scheduled reporting date on file.

Trials on file: 29
Active: 1
Active phase 3: 1
Participants in active trials: 63
Sponsors: 24
Scheduled readouts: 0

All trials on file

Every registered trial of exenatide grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Weight Loss With Exenatide Treatment NCT01590433	Completed	P4	Jody Dushay
Research of Exenatide for Overweight/Obese PCOS Patients With IGR NCT03352869	Completed	P4	RenJi Hospital
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients NCT00500370	Completed	P2	AstraZeneca
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects NCT00856609	Completed	P3	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Exenatide for Smoking Cessation and Prevention of Weight Gain NCT05610800	Completed	P2	The University of Texas Health Science Center, Houston
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) NCT02635386	Completed	P3	Woman's
Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity NCT02496611	Completed	P2	University of Minnesota
Liver and Fat Regulation in Overweight Adolescent Girls NCT02157974	Completed	P2/P3	University of Colorado, Denver
DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2 NCT03361098	Completed	P4	Amsterdam UMC, location VUmc
Brain Activation and Satiety in Children 2 NCT04520490	Active, not recruiting	P3	Seattle Children's Hospital
Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults NCT00845507	Completed	P4	University of Cincinnati
Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight NCT02313220	Completed	P2	Uppsala University
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue NCT01794429	Completed	P3	Bjorn H. Ebdrup
Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI NCT02794402	Completed	P2	Uppsala University
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics NCT02042664	Completed	P3	Assistance Publique Hopitaux De Marseille
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity NCT02664441	Completed	P3	Seattle Children's Hospital
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy NCT02860923	Completed	P3	University Hospital, Bordeaux
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women NCT00456885	Completed	P4	Beth Israel Deaconess Medical Center
The Effects of Exenatide After Gastric Restriction NCT00872378	Unknown	P2/P3	Advanced Specialty Care
Exenatide in Extreme Pediatric Obesity NCT01237197	Completed	P2	University of Minnesota
Exenatide and Brown Adipose Tissue NCT03002675	Unknown	P4	Ingrid Jazet
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes NCT02104739	Completed	P4	The University of Texas Health Science Center, Houston
GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men NCT02170324	Completed	P4	Xiang Guang-da
Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying NCT02160990	Completed	P4	Mayo Clinic
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients NCT03419624	Terminated	P3	Universitätsklinikum Hamburg-Eppendorf
GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children NCT00886626	Completed	P2	University of Minnesota
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes NCT04307797	Completed	P4	Cambridge University Hospitals NHS Foundation Trust
Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor NCT01484873	Completed	P2	Vanderbilt University Medical Center
The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults NCT00845559	Withdrawn	P4	Yale University

See the full record for exenatide, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.

Get the briefing

exenatide in obesity & overweight

All trials on file